Bender Robert & Associates Exelixis, Inc. Call Options Transaction History
Bender Robert & Associates
- $471 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding EXEL
# of Institutions
466Shares Held
240MCall Options Held
2.04MPut Options Held
1.29M-
Black Rock Inc. New York, NY33.5MShares$1.17 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.7MShares$1.03 Billion0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA27.1MShares$943 Million2.95% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.2MShares$527 Million0.6% of portfolio
-
State Street Corp Boston, MA12.6MShares$438 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.2B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...